





#### **COVID-19 Research at VIDO-InterVac:**


### **Working for Canadians and Canada's Economy**

**Volker Gerdts, Director and CEO** 



## VIDO-InterVac is....

- A global leader in infectious disease and vaccine research
- 45 years of expertise in human and animal health.
- About 150 staff, \$20 Million annual budget
- Some of the most advanced infrastructure in Canada and world.
- Research Centre at the University of Saskatchewan.







commercialized vaccines... 6 world firsts



4 Spin-off companies



Certified to ISO 9001





>1000 published research papers





## **Economic Impacts**



Product	Sector	Application	Disease impact/year
Vicogen™	Cattle	Calf scours	\$ 300 million
Ecolan RC™	Cattle	Bacterial and viral calf scours	\$ 300 million
Hevlan TC™	Poultry	Enteritis in turkeys	\$ 20 million
Pneumo-Star™	Cattle	Pasteurellosis (part of BRD comple	ex) \$1 billion
Somnu-Star™	Cattle	Haemophilosis (part of BRD comp	lex) \$1 billion
Somnu-Star Ph™	Cattle	Pasteurellosis and Haemophilosis	\$ 1 billion
Pleuro-Star 4 <sup>™</sup>	Swine	Porcine Pleuropneumonia	\$ 100 million
<b>Econiche</b> <sup>™</sup>	Cattle	Food safety - E. coli O157:H7	\$ 100 million
PEDV	Swine	Neonatal diarrhea	\$ 300 million
CBPP	Cattle	Lung Plaque	\$ 100 million

Next vaccines entering clinical phase are COVID-19 and RSV/PI3 vaccines





## VIDO-InterVac Board of Directors

#### **Organizations represented:**

- Novartis Sandoz, Switzerland
- Canadian Beef Industry
- Canadian Pork Industry
- Dairy Farmers of Canada
- US Department of Health
- Singapore Public Health
- Texas A&M University
- ILRI, Kenya
- Government of Alberta
- Government of Saskatchewan
- University of Saskatchewan





### COVID-19 research at VIDO-InterVac

- 1st in Canada to isolate virus (with Sunnybrook and NML)
- 1st in Canada to establish ferret and hamster model
- Vaccine candidate under development
- Member of 3 World Health
  Organization (WHO) expert groups
- Contract research: > 70 contracts to evaluate candidate antivirals, vaccines and therapeutics







## VIDO-InterVac's COVID-19 Vaccine

- Vaccine Design completed (Jan. 2020)
- Produced at lab scale (Jan. Feb. )
- Proof-of concept (March June)
- GMP Manufacturing (March November)
- Toxicology studies (Sept November)
- Human clinical trials (Dec. April. 2021)

Presentation to Canada's Vaccine TaskForce







## **COVID-19 Contract Research**


- Total > 70 contracts
  - 50% Canadian
  - 50% International
- Testing of:
  - novel antivirals
  - therapeutics
  - vaccine candidates
- ISO 9001, dedicated contract research group, certified project managers, etc.
- Funded through MSI (CFI) and Gov't of Saskatchewan







# Construction of pilot-scale manufacturing facility







## Adding to Canada's capacity for biomanufacturing

- Unique in the world to be able to produce both bacterial and mammalian-based vaccines including biocontainment Level III
- Animal Health:
  - Full-licensure, commercial manufacturing
- Human Health:
  - Process Development, material for phase I-III clinical trials
  - Production during pandemics/emergencies
- Could produce 20-40 million doses per year (depending on vaccine)





## Lessons learned.....

- Infectious diseases have significant impact
- Quick response is critical
  - Vertically-integrated, in-house
  - Platform technologies
- Establishment of national centers focused on emerging diseases

#### Sept 10th, 2020




Deadly Hog Fever Found in Germany, Europe's Top Pork Producer

- Disease of pigs, humans not susceptible
- Major threat to Canadian Pork industry
- Economic impact \$\$\$ billions
- Trade issue (other countries immediately stop trading of live pigs or meat products)
- No vaccines available





## VIDO-InterVac: Canada's "Centre for Pandemic Research"



#### In place:

- Canada's largest high containment laboratory
- Manufacturing facility
- Collaboration with NML and CFIA in Winnipeg

#### Needed:

- New animal facility: Ability to work with wide range of animals, exotic species, insects etc.
- Upgrade to containment level IV





#### Zika virus



#### **MERS-CoV**



#### PEDV (pigs)



#### **African Swine Fever (pigs)**



1st in the world to develop model in pregnant pigs (6 months). Used by industry to evaluate vaccines and therapeutics

1st in the world to develop "One Health Vaccine" (16 months). Partnered with Saudi Govt. and companies in UAE

1st in Canada to develop vaccine for pigs (16 months). Licensed to pharma industry

1st non-Government lab in Canada permitted to work with virus. Vaccine development under way



## Proposal to establish "Centre for Pandemic Research"

- Partnership private, industry and all levels of government
  - Gov't of Canada (ongoing)
  - Gov't of Saskatchewan (committed)
  - Fundraising campaign underway (ongoing)
- Seeking funding for:
  - Infrastructure and equipment:
    - Build new animal facility,
    - Upgrade existing facility to containment level 4
  - Experts:
    - Recruit global international experts
    - Train next generation of decision makers
    - Help to "build back better" prepare Canada for next disease

